Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Anaya, Meisser Vidal Madera; Amador, Lesbia Rosa Tirado; Acosta, Carlos Leal

doi:10.2147/cmar.s283204

Cited by 10 publications

(5 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion criteria derived from this framework were: (i) both prospective and retrospective studies investigating PD‐L1 expression in samples procured from primary and naive OSCC patients; and (ii) studies that reported survival indexes based on calculating multivariable hazard ratio (HR) and its 95% confidence interval (95% CI) for at least OS and/or DFS. Our meta‐analysis adhered to existing guidelines, including Meta‐analyses Of Observational Studies in Epidemiology (MOOSE) guidelines (Stroup, 2000 ), Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA), and the Newcastle‐Ottawa Scale (NOS) statement (Liberati et al, 2009 ; Mattox et al, 2017 ). Studies not dealing with OSCC, not reporting PD‐L1 positive and negative expression, or not reporting survival data in an extractable manner were excluded, as were studies represented by abstracts only or other article types, such as letters, reviews, animal and cell culture studies, and case reports.…”

Section: Methodsmentioning

confidence: 99%

PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside

Nocini

Matteo

Girolami

et al. 2022

Clinical & Exp Dental Res

View full text Add to dashboard Cite

Objectives and background: Oral squamous cell carcinoma (OSCC) is a highly malignant disease with an increasing incidence. The need to improve therapeutic strategies for patients affected by OSCC is an urgent challenge. Currently, the advent of immunotherapy represents an important step toward this aim. Programmed cell deathligand 1 (PD-L1), a membrane protein that can be expressed on tumor and inflammatory cells is a key biomarker whose expression is determined by means of immunohistochemistry and is necessary for selecting patients for immunotherapy.Methods: In this study, we review the methods of PD-L1 assessment and outcomes achieved with immunotherapy in the treatment of OSCC patients.Results: Based on a meta-analysis we demonstrate a lack of prognostic significance of PD-L1 in OSCC. Conclusions:We also highlight unresolved issues including difficulties in standardizing PD-L1 evaluation and discuss future opportunities such as leveraging digital pathology.

show abstract

Section: Methodsmentioning

confidence: 99%

PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside

Nocini

Matteo

Girolami

et al. 2022

Clinical & Exp Dental Res

View full text Add to dashboard Cite

show abstract

“…Oral squamous cell carcinoma (OSCC) refers to squamous cell carcinoma originating in the oral cavity, including the cheeks, lips, mouth floor, tongue, and palate. It is one of the common head and neck malignant tumors worldwide ( 1 , 2 ). There are almost 300,000 new cases of OSCC each year, and about 170,000 related deaths ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics based exploration of hsa-miR-194-5p regulation of CHD4 through PI3K/AKT signal pathway to enhance tumor resistance to apoptosis due to loss of nests and participate in poor prognosis of oral squamous cell carcinoma

Li¹,

Wang²,

Shen³

et al. 2023

Ann Transl Med

View full text Add to dashboard Cite

Background Recent evidence shows that CHD4 is involved in a variety of biological events of tumors. Our aim was to investigate the correlation between CHD4 and oral squamous cell carcinoma (OSCC). Methods After CHD4 was screened as a differentially expressed gene in The Cancer Genome Atlas (TGCA) database, the correlations of its expression level with the clinical parameters and prognosis of patients with OSCC were analyzed. The outcomes of the multivariate analysis were used to construct a nomogram, and the accuracy of the model was evaluated with the calibration curve. The GeneMANIA and STRING databases were used to generate network diagrams depicting interactions of genes with CHD4, and heat maps of genes co-expressed with CHD4 were generated using the TCGA database. TargetScan was then used to look into the miRNAs that interact with the 3' untranslated region of CHD4 mRNA. Finally, GSEA enrichment analysis was used to explore the possible mechanism. Results The differentially expressed molecule CHD4 was screened by TCGA database for OSCC. CHD4 was overexpressed in OSCC tumor tissues, and OSCC patients with low expression of CHD4 have better OS and DSS. The nomogram had a C-index of 0.575 (0.548–0.602), which indicated some degree of predictive reliability. CHD4 has certain correlation with exons of OSCC related genes, including TP53 , NOTCH1 , CASP8 , PTEN , TP63 , ANXA1 , CDH1 , CTNNB1 , GDF15 and EGFR . According to the TargetScan database, hsa-miR-194-5p is the miRNA that regulates CHD4 upstream the most. GSEA analysis showed that CHD4 may participate in the poor prognosis of OSCC by participating in PI3K/AKT pathway, protein adhesion regulation, MAPK pathway, cytokine and inflammatory response regulation, angiogenesis and platelet regulation. Conclusions The decreased expression of CHD4 may indicate a better prognosis in OSCC patients and could serve as a novel predictive biomarker for OSCC. Also, hsa-miR-194-5p was found to contribute to the poor prognosis of OSCC by regulating CHD4 and enhancing tumor anoikis resistance via the PI3K/AKT signaling pathway. These findings suggest that CHD4 might be a therapeutic target for the effective treatment of OSCC.

show abstract

“…As a predominant form of oral cancer, oral squamous cell carcinoma (OSCC) not only affects the lips, tongue, gums, floor of the mouth, and hard and soft palates, but also metastasizes to other parts of the body if not treated in time 1 . The various and complex risk factors which influence OSCC include smoking habits, alcohol use, poor oral hygiene, exposure to human papillomavirus (HPV), or even disease histories such as head and neck cancer 2 . It is crucial to understand the molecular changes during the development and progression of OSCC to improve OSCC patients' survival rates and reduce recurrence 3 …”

Section: Introductionmentioning

confidence: 99%

miR‐19a may function as a biomarker of oral squamous cell carcinoma (OSCC) by regulating the signaling pathway of miR‐19a/GRK6/GPCRs/PKC in a Chinese population

Chen,

Wang,

et al. 2023

J Oral Pathology Medicine

View full text Add to dashboard Cite

BackgroundIn this study, we aimed to investigate the potential of miR‐19a as a biomarker of OSCC and its underlying molecular mechanisms.MethodsWe collected serum and saliva samples from 66 OSCC patients and 66 healthy control subjects. Real‐time PCR analysis, bioinformatic analysis and luciferase assays were performed to establish a potential signaling pathway of miR‐19a/GRK6/GPCRs/PKC. Flowcytometry and Transwell assays were performed to observe the changes in cell apoptosis, metastasis and invasion.ResultsWe found that miR‐19a, GPR39 mRNA and PKC mRNA were upregulated while GRK6 mRNA was downregulated in the serum and saliva samples collected from OSCC patients. Moreover, in silico analysis confirmed a potential binding site of miR‐19a on the 3′UTR of GRK6 mRNA, and the subsequent luciferase assays confirmed the molecular binding between GRK6 and miR‐19a. We further identified that the over‐expression of miR‐19a could regulate the signaling between GRK6, GPR39 and PKC via the signaling pathway of miR‐19a/GRK6/GPR39/PKC, which accordingly resulted in suppressed cell apoptosis and promoted cell migration and invasion.ConclusionCollectively, the findings of our study propose that miR‐19a is a crucial mediator in the advancement of OSCC, offering a potential avenue for the development of innovative therapeutic interventions aimed at regulating GRK6 and its downstream signaling pathways.

show abstract

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Cited by 10 publications

References 60 publications

PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside

PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside

Bioinformatics based exploration of hsa-miR-194-5p regulation of CHD4 through PI3K/AKT signal pathway to enhance tumor resistance to apoptosis due to loss of nests and participate in poor prognosis of oral squamous cell carcinoma

miR‐19a may function as a biomarker of oral squamous cell carcinoma (OSCC) by regulating the signaling pathway of miR‐19a/GRK6/GPCRs/PKC in a Chinese population

Contact Info

Product

Resources

About